Contineum Therapeutics Email Format

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

Contineum Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing oral small molecule therapies for neuroscience, inflammation and immunology indications. The company operates in the pharmaceutical manufacturing industry and advances an internally developed pipeline with multiple drug candidates in clinical trials. Pipeline programs include PIPE-791, an LPA1 receptor antagonist in development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307, a selective M1 receptor inhibitor in development for relapsing-remitting multiple sclerosis and major depressive disorder. Contineum Therapeutics is publicly listed on Nasdaq with the ticker CTNM and has 51-200 employees. Recent governance updates include the appointment of Diego Miralles, M.D., to its board of directors in March 2025.

Get verified Contineum Therapeutics emails free

Company overview Employee directory